Los	O
estudios	B-Claim
de	I-Claim
fase	I-Claim
II	I-Claim
y	I-Claim
III	I-Claim
han	I-Claim
demostrado	I-Claim
que	I-Claim
la	I-Claim
adición	I-Claim
de	I-Claim
interleucina-2	I-Claim
(	I-Claim
IL-2	I-Claim
)	I-Claim
e	I-Claim
interferón	I-Claim
alfa-2b	I-Claim
(	I-Claim
IFN	I-Claim
alfa-2b	I-Claim
)	I-Claim
en	I-Claim
la	I-Claim
quimioterapia	I-Claim
multifarmacológica	I-Claim
(	I-Claim
QT	I-Claim
)	I-Claim
para	I-Claim
el	I-Claim
melanoma	I-Claim
avanzado	I-Claim
aumenta	I-Claim
la	I-Claim
respuesta	I-Claim
global	I-Claim
(	I-Claim
OR	I-Claim
)	I-Claim
,	I-Claim
aunque	I-Claim
sin	I-Claim
una	I-Claim
respuesta	I-Claim
clara	I-Claim
evidencia	I-Claim
de	I-Claim
una	I-Claim
mejora	I-Claim
en	I-Claim
la	I-Claim
supervivencia	I-Claim
general	I-Claim
(	I-Claim
SG	I-Claim
)	I-Claim
.	I-Claim

El	O
tratamiento	B-Claim
con	I-Claim
dosis	I-Claim
altas	I-Claim
de	I-Claim
IL-2	I-Claim
puede	I-Claim
causar	I-Claim
toxicidad	I-Claim
grave	I-Claim
y	I-Claim
,	I-Claim
por	I-Claim
lo	I-Claim
general	I-Claim
,	I-Claim
se	I-Claim
administra	I-Claim
en	I-Claim
un	I-Claim
entorno	I-Claim
hospitalario	I-Claim
.	I-Claim

Realizamos	O
un	O
ensayo	O
clínico	O
aleatorizado	O
prospectivo	O
multicéntrico	O
en	O
pacientes	O
ambulatorios	O
con	O
melanoma	O
metastásico	O
para	O
comparar	O
la	O
TC	O
con	O
la	O
bioquimioterapia	O
(	O
bioCT	O
)	O
utilizando	O
dosis	O
inmunomoduladoras	O
de	O
IL-2	O
e	O
IFN	O
alfa-2b	O
.	O

Ciento	O
setenta	O
y	O
seis	O
pacientes	O
elegibles	O
con	O
melanoma	O
avanzado	O
fueron	O
aleatorizados	O
para	O
recibir	O
CT	O
(	O
cisplatino	O
y	O
dacarbazina	O
con	O
o	O
sin	O
carmustina	O
cada	O
21	O
días	O
)	O
o	O
bioCT	O
que	O
comprende	O
el	O
mismo	O
régimen	O
de	O
CT	O
seguido	O
de	O
dosis	O
bajas	O
de	O
IL-2	O
subcutánea	O
durante	O
8	O
días	O
e	O
IFN	O
alfa	O
-	O
2b	O
tres	O
veces	O
por	O
semana	O
,	O
ambos	O
durante	O
seis	O
ciclos	O
.	O

En	B-Premise-Support-4
una	I-Premise-Support-4
mediana	I-Premise-Support-4
de	I-Premise-Support-4
seguimiento	I-Premise-Support-4
de	I-Premise-Support-4
18	I-Premise-Support-4
(	I-Premise-Support-4
CT	I-Premise-Support-4
)	I-Premise-Support-4
y	I-Premise-Support-4
16	I-Premise-Support-4
(	I-Premise-Support-4
bioCT	I-Premise-Support-4
)	I-Premise-Support-4
meses	I-Premise-Support-4
,	I-Premise-Support-4
la	I-Premise-Support-4
mediana	I-Premise-Support-4
de	I-Premise-Support-4
SG	I-Premise-Support-4
fue	I-Premise-Support-4
de	I-Premise-Support-4
9,5	I-Premise-Support-4
versus	I-Premise-Support-4
11,0	I-Premise-Support-4
meses	I-Premise-Support-4
(	I-Premise-Support-4
P	I-Premise-Support-4
=	I-Premise-Support-4
0,51	I-Premise-Support-4
)	I-Premise-Support-4
,	I-Premise-Support-4
respectivamente	I-Premise-Support-4
.	I-Premise-Support-4

En	B-Premise-Support-3
los	I-Premise-Support-3
89	I-Premise-Support-3
pacientes	I-Premise-Support-3
del	I-Premise-Support-3
grupo	I-Premise-Support-3
de	I-Premise-Support-3
TC	I-Premise-Support-3
,	I-Premise-Support-3
se	I-Premise-Support-3
observaron	I-Premise-Support-3
18	I-Premise-Support-3
OR	I-Premise-Support-3
(	I-Premise-Support-3
20,2	I-Premise-Support-3
%	I-Premise-Support-3
)	I-Premise-Support-3
(	I-Premise-Support-3
3	I-Premise-Support-3
respondedores	I-Premise-Support-3
completos	I-Premise-Support-3
[	I-Premise-Support-3
RC	I-Premise-Support-3
]	I-Premise-Support-3
y	I-Premise-Support-3
15	I-Premise-Support-3
respondedores	I-Premise-Support-3
parciales	I-Premise-Support-3
[	I-Premise-Support-3
PR	I-Premise-Support-3
]	I-Premise-Support-3
)	I-Premise-Support-3
según	I-Premise-Support-3
los	I-Premise-Support-3
criterios	I-Premise-Support-3
de	I-Premise-Support-3
la	I-Premise-Support-3
Organización	I-Premise-Support-3
Mundial	I-Premise-Support-3
de	I-Premise-Support-3
la	I-Premise-Support-3
Salud	I-Premise-Support-3
.	I-Premise-Support-3

En	B-Premise-Support-2
los	I-Premise-Support-2
87	I-Premise-Support-2
pacientes	I-Premise-Support-2
del	I-Premise-Support-2
brazo	I-Premise-Support-2
bioCT	I-Premise-Support-2
,	I-Premise-Support-2
se	I-Premise-Support-2
registraron	I-Premise-Support-2
22	I-Premise-Support-2
OR	I-Premise-Support-2
(	I-Premise-Support-2
25,3	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
(	I-Premise-Support-2
3	I-Premise-Support-2
CR	I-Premise-Support-2
y	I-Premise-Support-2
19	I-Premise-Support-2
PR	I-Premise-Support-2
)	I-Premise-Support-2
(	I-Premise-Support-2
p	I-Premise-Support-2
=	I-Premise-Support-2
0,70	I-Premise-Support-2
)	I-Premise-Support-2
.	I-Premise-Support-2

La	O
toxicidad	B-Premise-Support-3
relacionada	I-Premise-Support-3
con	I-Premise-Support-3
el	I-Premise-Support-3
tratamiento	I-Premise-Support-3
fue	I-Premise-Support-3
bastante	I-Premise-Support-3
similar	I-Premise-Support-3
en	I-Premise-Support-3
ambos	I-Premise-Support-3
brazos	I-Premise-Support-3
.	I-Premise-Support-3

La	B-Claim
adición	I-Claim
de	I-Claim
inmunoterapia	I-Claim
en	I-Claim
dosis	I-Claim
bajas	I-Claim
no	I-Claim
produjo	I-Claim
una	I-Claim
ventaja	I-Claim
estadísticamente	I-Claim
significativa	I-Claim
en	I-Claim
la	I-Claim
SG	I-Claim
,	I-Claim
el	I-Claim
tiempo	I-Claim
hasta	I-Claim
la	I-Claim
progresión	I-Claim
o	I-Claim
la	I-Claim
OR	I-Claim
.	I-Claim

Sin	O
embargo	B-Claim-Partial_Attack--1
,	I-Claim-Partial_Attack--1
la	I-Claim-Partial_Attack--1
mediana	I-Claim-Partial_Attack--1
de	I-Claim-Partial_Attack--1
SG	I-Claim-Partial_Attack--1
de	I-Claim-Partial_Attack--1
11	I-Claim-Partial_Attack--1
meses	I-Claim-Partial_Attack--1
en	I-Claim-Partial_Attack--1
el	I-Claim-Partial_Attack--1
brazo	I-Claim-Partial_Attack--1
bioCT	I-Claim-Partial_Attack--1
no	I-Claim-Partial_Attack--1
difiere	I-Claim-Partial_Attack--1
mucho	I-Claim-Partial_Attack--1
de	I-Claim-Partial_Attack--1
los	I-Claim-Partial_Attack--1
mejores	I-Claim-Partial_Attack--1
resultados	I-Claim-Partial_Attack--1
con	I-Claim-Partial_Attack--1
regímenes	I-Claim-Partial_Attack--1
que	I-Claim-Partial_Attack--1
contienen	I-Claim-Partial_Attack--1
IL-2	I-Claim-Partial_Attack--1
en	I-Claim-Partial_Attack--1
dosis	I-Claim-Partial_Attack--1
altas	I-Claim-Partial_Attack--1
informados	I-Claim-Partial_Attack--1
en	I-Claim-Partial_Attack--1
la	I-Claim-Partial_Attack--1
literatura	I-Claim-Partial_Attack--1
.	I-Claim-Partial_Attack--1

Además	O
,	O
nuestro	B-Claim
esquema	I-Claim
de	I-Claim
tratamiento	I-Claim
se	I-Claim
realizó	I-Claim
de	I-Claim
forma	I-Claim
ambulatoria	I-Claim
y	I-Claim
tuvo	I-Claim
un	I-Claim
nivel	I-Claim
de	I-Claim
toxicidad	I-Claim
aceptable	I-Claim
.	I-Claim

